We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
FDA’s drug safety initiative: Resolutions or more questions?
- Authors
Young, Donna
- Abstract
This article focuses on the United States Food and Drugs Administration's (FDA) drug safety initiative. John K. Jenkins, director of FDA's Office of New Drugs, maintained that regulators in 2002 says that they were going through the process of making sure that the public was aware of the risks of using rofecoxib after FDA asked Merck to add information to the drug's labeling reflecting the findings of the Vioxx Gastrointestinal Outcomes Research study, which found an increased risk of serious cardiovascular events.
- Publication
American Journal of Health-System Pharmacy, 2005, Vol 62, Issue 13, p1333
- ISSN
1079-2082
- Publication type
Academic Journal
- DOI
10.2146/news050001